#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Colorectal cancer metastatic Obesity Prostate cancer Crohn's disease Colorectal cancer Ovarian cancer Dementia Alzheimer's type Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Alport's syndrome Usher's syndrome Alveolar rhabdomyosarcoma Haematological malignancy PIK3CA-activated mutation Glycogen storage disease type II Glioblastoma multiforme Endocrine ophthalmopathy Follicle centre lymphoma follicular grade I, II – III Laryngeal squamous cell carcinoma Bronchopulmonary dysplasia Staphylococcal infection Anaplastic large cell lymphoma T- and null-cell types Mantle cell lymphoma Metastatic malignant melanoma More trials…

    Learn about Rare Diseases

    Bronchiolitis obliterans syndrome – Treatment Lymphatic malformation – Diagnostics Congenital nephrogenic diabetes insipidus – Diagnostics Fabry’s disease – Diagnostics Alveolar rhabdomyosarcoma – Life with Disease Leiomyosarcoma metastatic – Treatment Cystic fibrosis lung – Treatment Chordoma Advanced systemic mastocytosis – Basic Information Mastocytosis – Life with Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Lenalidomide Tryptophan Calcium Carbonate Namilumab Emraclidine Sotrovimab Lurasidone Clofarabine Levetiracetam Immunoglobulin A ICEF15 Nebivolol Hydrochloride Dobutamine Emedastine 4-Hydroxy-N-Desmethyltamoxifen Padeliporfin Tazobactam Sodium Retinol Acetate IHMA-2121771-2 Ptg-Carcik-Cd19 More therapies…

    Learn about Your Condition

    Transitional cell carcinoma Myeloproliferative neoplasm Gingival bleeding Sciatica Mucosal inflammation Aplasia pure red cell Conjunctivitis allergic Embolism Netherton's syndrome Biliary cancer metastatic Arterial stiffness Andersen-Tawil syndrome Left ventricular failure Proteinuria Premature baby More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Mantle cell lymphoma stage II

  • Study on CAR-T-cell Therapy with Rituximab and Ibrutinib for Patients with High-Risk Mantle Cell Lymphoma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Brexucabtagene Autoleucel
    • Bendamustine
    • Melphalan
    Czechia France Germany The Netherlands Spain

  • Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Mantle cell lymphoma stage II
    • Mantle cell lymphoma stage III
    • Mantle cell lymphoma stage IV
    Investigated Drugs:
    • Ibrutinib
    Belgium Czechia Denmark Finland Germany Italy +6

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!